Oct 2026· Journal of Medicinal Chemistry· Vol 69 20, pp.
24053-24067
· 0 citations· 45 references
Medicine
TL;DR
Four 68Ga-labeled CAIX-targeting probes based on the acetazolamide (AAZ) scaffold are reported, employing distinct conjugation strategies, including amide coupling and maleimide-thiol ligation, representing a promising candidate for imaging CAIX-overexpressing tumors and supporting clinical translation.
Abstract
Carbonic anhydrase IX (CAIX) is a well-established biomarker of tumor hypoxia and an attractive target for molecular imaging. Despite the development of small-molecule CAIX-targeting positron emission tomography (PET) probes, most exhibit high normal-organ uptake and suboptimal tumor-to-background contrast. Moreover, their application in hypoxic tumors remains insufficiently explored. Herein, we reported four 68Ga-labeled CAIX-targeting probes based on the acetazolamide (AAZ) scaffold, employing distinct conjugation strategies, including amide coupling and maleimide-thiol ligation. All probes demonstrated detectable tumor uptake in vivo. Among them, [68Ga]Ga-SMIC-2607 displayed the highest tumor uptake (14.67 ± 3.06 %ID/g) and tumor-to-kidney ratio (1.69 ± 0.41) at 1 h in subcutaneous OS-RC-2-bearing mice, along with high tumor uptake in HT-29-bearing mice (2.98 ± 0.28 %ID/g at 1 h). Overall, [68Ga]Ga-SMIC-2607 demonstrates favorable imaging characteristics, with high tumor uptake and high tumor-to-normal organ ratios, representing a promising candidate for imaging CAIX-overexpressing tumors and supporting clinical translation.
Carbonic anhydrase IX (CAIX) is a key biomarker for clear cell renal cell carcinoma (ccRCC) PET imaging. The reported probe 68Ga-DPI-4452 strongly targets both hCAIX and hCAII, therefore hindering its clinical applications. This study developed two optimized probes, 68Ga-WF1 and 68Ga-WF2. They have nanomolar affinity...
Fu-Hai Wu, Zhen Chen, Huang-You Chen et al.· Journal of Medicinal Chemist...· 0 citations
Small molecule nanodrugs (SMNs) offer unique advantages for cancer therapy, yet accurately tracking their in vivo fate without perturbing their native assembly remains challenging. Here, we report a spacer engineering strategy that enables efficient 1 8F-labeling while preserving SMNs self-assembly. Erlotinib-based amp...
Jia-Feng Li, Yi-Ru Jiang, Ji-Wei Cui et al.· Small· 0 citations
Carbonic Anhydrase IX (CAIX) is an attractive biomarker for clear cell renal cell carcinoma (ccRCC), but small-molecule CAIX radiotracers are often limited by insufficient tumor retention and suboptimal tumor-to-kidney contrast. Herein, we report the rational design of biphenyl-containing bivalent sulfonamide tracers a...
Yi-Min Chen, Wan-Jia Liu, Ben Li et al.· Journal of Medicinal Chemist...· 0 citations
HER2-targeting affibody radioprobes are often limited by rapid systemic clearance and excessive renal accumulation. Herein, we develop a modular chemical strategy to optimize the pharmacokinetic properties of affibodies through conjugation of small-molecule albumin-binding motifs (ABMs). Enabled by our selective S-gl...
Wei-Chen Wang, Ao Shen, Ming-Xing Huang et al.· Journal of Medicinal Chemist...· 0 citations
Tumor heterogeneity limits the diagnostic performance of molecular imaging probes targeting a single biomarker. Here, we report the design, synthesis, and preclinical evaluation of 68Ga-labelled heterodimeric radiotracers co-targeting integrin αvβ3 and poly(ADP-ribose) polymerase 1 (PARP1) through a proposed "binding-a...
Cong-Jie He, Yun-Long Li, Peng-Fei Dai et al.· Journal of Medicinal Chemist...· 0 citations
Carbonic anhydrase IX (CA IX) is a key biomarker for tumor hypoxia and a promising target for molecular imaging. In this study, we developed [68Ga]Ga-DOTA-L3, a novel small-molecule CA IX-targeted PET tracer. The radiolabeling was optimized to consistently achieve a radiochemical purity of >98% (10 μg precursor, 90 °C,...
Jie Li, Yu-Hui Luo, Cheng-Yu Luo et al.· Molecular Pharmaceutics· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.